-
公开(公告)号：US20140112976A1
公开(公告)日：2014-04-24
申请号：US14005855
申请日：2012-03-21
申请人： María del Carmen Abrahantes Pérez , Glay Chinea Santiago , Eduardo Martínez Díaz , Hilda Elisa Garay Perez , Osvaldo Reyes Acosta , Ernesto Lopez Mola , Cruz Matilde Lopez Abad , Sonia Gonzalez Blanco
发明人： María del Carmen Abrahantes Pérez , Glay Chinea Santiago , Eduardo Martínez Díaz , Hilda Elisa Garay Perez , Osvaldo Reyes Acosta , Ernesto Lopez Mola , Cruz Matilde Lopez Abad , Sonia Gonzalez Blanco
IPC分类号： A61K38/12 , A61K31/4025 , A61K45/06 , C07K7/64
CPC分类号： A61K38/12 , A61K9/0019 , A61K9/127 , A61K9/5031 , A61K31/4025 , A61K38/00 , A61K45/06 , A61K47/60 , C07K7/06 , C07K7/08 , C07K7/64
摘要： The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.
摘要翻译： 本发明包括具有抗肿瘤和抗血管生成特性的环肽，以及它们相应的药学上合适的盐以及含有它的药物组合物。 这些环肽用于制备用于人和/或兽医治疗剂的药物，另外用于诊断。 这些化合物可用于检测，监测和/或控制一系列细胞增殖相关疾病，例如肿瘤疾病和不期望的血管生成。 此外，它们可以作为控制释放系统的一部分进行纳入，并且在纳米生物技术领域更加精确地使用，无论是由于其自组装能力还是作为其他系统的一部分。
-
22.发明授权公开(公告)号：US08691234B2
公开(公告)日：2014-04-08
申请号：US12430534
申请日：2009-04-27
申请人： Santiago Duenas Carrera , Juan Morales Grillo , Liz Alvarez-Lajonchere Ponce de Leon , Alexis Musacchio Lasa , Rolando Pajon Feyt , Ariel Vina Rodriguez , Julio C. Alvarez Obregon , Nelson Acosta Rivero , Gillian Martinez Donato
发明人： Santiago Duenas Carrera , Juan Morales Grillo , Liz Alvarez-Lajonchere Ponce de Leon , Alexis Musacchio Lasa , Rolando Pajon Feyt , Ariel Vina Rodriguez , Julio C. Alvarez Obregon , Nelson Acosta Rivero , Gillian Martinez Donato
IPC分类号： A61K39/00
CPC分类号： A61K39/29 , A61K39/12 , A61K39/292 , A61K2039/53 , A61K2039/55505 , A61K2039/70 , C12N2730/10134 , C12N2770/24234
摘要： Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens.These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.
摘要翻译： 包含作为主要成分的疫苗抗原的制剂：a-）在免疫个体中表达一种或几种蛋白质的一种或几种DNA，和b-以适当比例的病毒抗原。 开发新的配方，最大限度地减少增加和多样化针对不同病原体的免疫反应谱的组分数量，并产生抗病原体的联合疫苗。 这些制剂可以应用于制药工业中用于预防和/或治疗人类。
-
23.发明申请Recombinant Antibodies to the Vascular Endothelial Growth Factor (VEGF) which are Obtained by Means of Mutagenesis of Variable Regions 有权通过变异区域诱变获得的血管内皮生长因子（VEGF）的重组抗体公开(公告)号：US20140086829A1
公开(公告)日：2014-03-27
申请号：US13976060
申请日：2011-12-26
申请人： Humberto Lamdan Ordas , Jorge Victor Gavilondo Cowley , Marta Ayala Avila , Yasmiana Munoz Pozo , Amaury Pupo Merino , Gertrudis Rojas Dorantes , Lincidio Perez Sanchez
发明人： Humberto Lamdan Ordas , Jorge Victor Gavilondo Cowley , Marta Ayala Avila , Yasmiana Munoz Pozo , Amaury Pupo Merino , Gertrudis Rojas Dorantes , Lincidio Perez Sanchez
CPC分类号： C07K16/22 , A61K51/1021 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with to an increase in vasculature, such as age-related macular degeneration, cancer, and others.
摘要翻译： 本发明揭示识别人血管内皮生长因子A（VEGF-A）的人重组抗体，阻断其与VEGFR2受体的相互作用，并且干扰其在体内的增殖作用和促血管生成作用。 抗体鉴定了与之前报道的任何其它VEGF不同的人VEGF-A上的表位，并且通过将一个免疫球蛋白轻链可变区与其他三个重链可变区组合获得。 通过人免疫球蛋白可变区诱变获得抗体，并且可用于与脉管系统增加相关的病理实体的免疫治疗，例如年龄相关性黄斑变性，癌症等。
-
24.发明申请MONITORING OF IMMUNE SYSTEM USING PERIPHERAL BLOOD MICRO-RNA EXPRESSION PROFILE ANALYSIS AND USES THEREOF 审中-公开使用外周血微量RNA表达谱分析及其用途监测免疫系统公开(公告)号：US20130165497A1
公开(公告)日：2013-06-27
申请号：US13703730
申请日：2011-06-15
IPC分类号： C12Q1/68 , A61K31/7105
CPC分类号： C12Q1/6883 , C12Q2600/158 , C12Q2600/178
摘要： The present invention relates to a method for monitoring the immune system of an individual, which comprises measuring, preferably by quantitative RT-PCR, the expression level of at least one microRNA (miRNA) gene product in a peripheral blood sample or in a biological fluid sample, and comparing said measured expression level with a reference level. In particular, the at least one miRNA gene product, which the method of the invention measures, is expressed by lymphocyte populations of an individual, in particular by naive CD4+T, TH1, TH2 and TH17 lymphocytes. The method of the invention is useful for the diagnosis, prognosis, prevention, control and/or the treatment of a pathological condition caused by or associated with an immune system dysfunction. Moreover, the method of the present invention is useful for monitoring, in an individual, the evolution of conditions mediated by the immune system, such as the response to a vaccination.
摘要翻译： 本发明涉及一种用于监测个体的免疫系统的方法，其包括优选通过定量RT-PCR测量外周血样品或生物液体中至少一种微小RNA（miRNA）基因产物的表达水平 采样，并将所述测量的表达水平与参考水平进行比较。 特别地，本发明的方法测量的至少一种miRNA基因产物由个体的淋巴细胞群体特别是天然的CD4 + T，TH1，TH2和TH17淋巴细胞表达。 本发明的方法可用于诊断，预后，预防，控制和/或治疗由免疫系统功能障碍引起或与免疫系统功能障碍相关的病理状况。 此外，本发明的方法可用于在个体中监测由免疫系统介导的病症的进化，例如对疫苗接种的反应。
-
公开(公告)号：US08409562B2
公开(公告)日：2013-04-02
申请号：US12280055
申请日：2007-02-28
申请人： Jorge Roberto Toledo Alonso , Oliberto Sánchez Ramos , Maritza Isidra Barrera Valle , Nancy Elena Figueroa Baile , Yanet Prieto Carratala , Maria Pilar Rodriguez Molto , Maria Teresa Frias Lepoureau , Carlos Guillermo Borroto Nordelo
发明人： Jorge Roberto Toledo Alonso , Oliberto Sánchez Ramos , Maritza Isidra Barrera Valle , Nancy Elena Figueroa Baile , Yanet Prieto Carratala , Maria Pilar Rodriguez Molto , Maria Teresa Frias Lepoureau , Carlos Guillermo Borroto Nordelo
CPC分类号： C07K14/005 , A01K2267/01 , A61K39/12 , A61K2039/55 , A61K2039/552 , A61K2039/55566 , A61K2039/57 , A61K2039/6031 , C07K14/70575 , C07K16/1081 , C07K2317/76 , C07K2319/21 , C07K2319/74 , C12N2710/10343 , C12N2770/24322 , C12N2770/24334
摘要： The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.
摘要翻译： 本发明描述了针对导致经典猪瘟（CSFV）的病毒的嵌合疫苗抗原。 这种疫苗抗原基于与能够刺激细胞和体液免疫系统的蛋白质偶联的病毒亚基。 嵌合抗原可以在保证构成本发明精华的嵌合分子的正确三级结构折叠的表达系统中产生。 含有这种嵌合抗原的疫苗制剂在接种疫苗的猪上诱导早期有效的免疫应答并赋予对CSFV的完全保护。 此外，所得疫苗制剂防止病毒从母猪传播到其后代。 嵌合抗原以及得到的疫苗制剂可以作为预防用于猪的疫苗用于动物健康。
-
26.发明授权Peptides and altered peptide ligands derived from HSP60 and pharmaceutical compositions 有权衍生自HSP60的肽和改变的肽配体和药物组合物公开(公告)号：US08324164B2
公开(公告)日：2012-12-04
申请号：US12649687
申请日：2009-12-30
申请人： Maria del Carmen Domínguez Horta , Gabriel Ramón Padrón Palomares , Nelia López Marin , Norailys Lorenzo Perez , Ariana Barberá Betancourt , Ariadna Hernández Garcia , Vivian Morera Cordova , Carelia Cosme Diaz , Nelson J. Merino Garcia , Ariel Vázquez Bonachea , José Suárez Alba
发明人： Maria del Carmen Domínguez Horta , Gabriel Ramón Padrón Palomares , Nelia López Marin , Norailys Lorenzo Perez , Ariana Barberá Betancourt , Ariadna Hernández Garcia , Vivian Morera Cordova , Carelia Cosme Diaz , Nelson J. Merino Garcia , Ariel Vázquez Bonachea , José Suárez Alba
摘要： Peptides of human heat shock protein of 60 kDa, that constitute epitopes for T cells, as well as their derived peptides, which are modified at the contact sites with the MHC molecule, are useful to induce mechanisms of peripheral tolerance, in particular mechanisms of anergy or mediated by clones of regulatory T cells in patients with Rheumatoid Arthritis. The invention also refers pharmaceutical compositions comprising such peptides for the treatment of Rheumatoid Arthritis.
摘要翻译： 构成T细胞表位的人类热休克蛋白的肽，以及它们衍生的肽，在与MHC分子的接触位点被修饰，可用于诱导外周耐受机制，特别是无反应机制 或由风湿性关节炎患者的调节性T细胞的克隆介导。 本发明还涉及包含这些肽用于治疗类风湿关节炎的药物组合物。
-
27.发明申请USE OF TELOCINOBUFAGIN AS AN ANALGESIC IN THE TREATMENT OF ACUTE AND CHRONIC PAINS; PHARMACEUTICAL COMPOSITION CONTAINING TELOCINOBUFAGIN AND ITS USE 失效在治疗急性和慢性疼痛中使用泰乐菌素作为药物; 含有TELOCINOBUFAGIN的药物组合物及其用途公开(公告)号：US20120077788A1
公开(公告)日：2012-03-29
申请号：US13322917
申请日：2010-05-26
申请人： Krishnamurti De Morais Carvalho , Dòris Maria Fernandes Carvalho , Maria Denise Fernandes Carvalho , Ogari de Castro Pacheco , Roberto Carlos Debom Moreira
发明人： Krishnamurti De Morais Carvalho , Dòris Maria Fernandes Carvalho , Maria Denise Fernandes Carvalho , Ogari de Castro Pacheco , Roberto Carlos Debom Moreira
IPC分类号： A61K31/585 , A61P29/00
CPC分类号： A61K31/585
摘要： The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.
摘要翻译： 本发明涉及telocinobufagin或其药学上可接受的衍生物在制备用于治疗或预防急性和慢性疼痛的药物中的用途。 本发明还涉及包含有效量的telocinobufagin的药物组合物; 还提供了一种诱导镇痛作用的方法，以应对急性和慢性疼痛，其理解向人或动物施用有效量的telocinobufagin。 根据体内测定的结果，telocinobufagin比吗啡更有效，尽管没有呈现阿片样物质的已知副作用。 此外，体内和体外散文表明，TBC不存在心脏毒性。
-
公开(公告)号：US08007776B2
公开(公告)日：2011-08-30
申请号：US10529923
申请日：2003-10-08
申请人： Alicia Santos Savio , Ricardo Silva Rodriguez , Yanelis Morera Diaz , Armando Alexei Rodriquez Alfonso , Jose Rafael Martinez Castillo , Haydee Geronimo Perez , Alejandro Moro Soria , Silvio Ernesto Perea Rodriguez
发明人： Alicia Santos Savio , Ricardo Silva Rodriguez , Yanelis Morera Diaz , Armando Alexei Rodriquez Alfonso , Jose Rafael Martinez Castillo , Haydee Geronimo Perez , Alejandro Moro Soria , Silvio Ernesto Perea Rodriguez
IPC分类号： A61K38/20
CPC分类号： A61K39/0005
摘要： Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host.IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide.Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.
摘要翻译： 含有IL-15的疫苗组合物用于主动免疫治疗与该细胞因子的过表达有关的疾病。 在本发明中追求的技术目的是通过开发在免疫宿主中引发IL-15中和抗体的治疗性疫苗来抑制IL-15活性。 IL-15可以单独存在于该疫苗组合物中，也可以与诸如氢氧化铝等疫苗佐剂的载体例如P64k蛋白偶联。 此外，本发明涉及该疫苗用于治疗类风湿性关节炎和其它IL-15过表达相关疾病和白血病，其中该细胞因子作为生长因子。
-
公开(公告)号：US07919463B2
公开(公告)日：2011-04-05
申请号：US11989088
申请日：2006-06-23
申请人： Jannel Acosta Alba , Mario Pablo Estrada Garcia , Yamila Carpio Gonzalez , Reynold Morales Fernandez
发明人： Jannel Acosta Alba , Mario Pablo Estrada Garcia , Yamila Carpio Gonzalez , Reynold Morales Fernandez
CPC分类号： C07K14/61 , A23K20/147 , A23K50/80 , C07K14/461 , C12N15/81
摘要： The present invention is related to polypeptides derived from tilapia growth hormone.
摘要翻译： 本发明涉及来源于罗非鱼生长激素的多肽。
-
30.发明申请公开(公告)号：US20100144642A1
公开(公告)日：2010-06-10
申请号：US12649687
申请日：2009-12-30
申请人： María del Carmen Domínguez Horta , Gabriel Ramón Padrón Palomares , Nelia López Marín , Norailys Lorenzo Perez , Ariana Barberá Betancourt , Ariadna Hernández Garcia , Vivian Morera Cordova , Carelia Cosme Díaz , Nelson J. Merino García , Ariel Vázquez Bonachea , José Suárez Alba
发明人： María del Carmen Domínguez Horta , Gabriel Ramón Padrón Palomares , Nelia López Marín , Norailys Lorenzo Perez , Ariana Barberá Betancourt , Ariadna Hernández Garcia , Vivian Morera Cordova , Carelia Cosme Díaz , Nelson J. Merino García , Ariel Vázquez Bonachea , José Suárez Alba
摘要： Peptides of human heat shock protein of 60 kDa, that constitute epitopes for T cells, as well as their derived peptides, which are modified at the contact sites with the MHC molecule, are useful to induce mechanisms of peripheral tolerance, in particular mechanisms of anergy or mediated by clones of regulatory T cells in patients with Rheumatoid Arthritis. The invention also refers pharmaceutical compositions comprising such peptides for the treatment of Rheumatoid Arthritis.
摘要翻译： 构成T细胞表位的人类热休克蛋白的肽，以及它们衍生的肽，在与MHC分子的接触位点被修饰，可用于诱导外周耐受机制，特别是无反应机制 或由风湿性关节炎患者的调节性T细胞的克隆介导。 本发明还涉及包含这些肽用于治疗类风湿关节炎的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
139 条记录 (耗时 0.021 秒)
